TCM
NBIX icon

Teza Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Teza Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,434
Closed -$306K – 213
2025
Q2 		$306K Sell
2,434
-2,870
-54% -$329K 0.23% 179
2025
Q1 		$587K Sell
5,304
-12,560
-70% -$1.59M 0.27% 118
2024
Q4 		$2.44M Buy
17,864
+765
+4% +$94.6K 0.37% 67
2024
Q3 		$1.97M Buy
17,099
+7,055
+70% +$967K 0.22% 137
2024
Q2 		$1.38M Buy
10,044
+5,359
+114% +$735K 0.17% 190
2024
Q1 		$646K Sell
4,685
-937
-17% -$128K 0.09% 295
2023
Q4 		$741K Sell
5,622
-3,117
-36% -$359K 0.12% 229
2023
Q3 		$983K Buy
+8,739
New +$920K 0.16% 187
2023
Q1 		– Sell
-15,691
Closed -$1.87M – 642
2022
Q4 		$1.87M Buy
15,691
+11,039
+237% +$1.29M 0.36% 66
2022
Q3 		$494K Buy
+4,652
New +$472K 0.1% 285
2020
Q3 		– Sell
-6,527
Closed -$796K – 531
2020
Q2 		$796K Buy
6,527
+2,746
+73% +$303K 0.18% 175
2020
Q1 		$327K Buy
3,781
+802
+27% +$78.5K 1.04% 33
2019
Q4 		$320K Buy
+2,979
New +$312K 0.09% 403
2017
Q2 		– Sell
-6,795
Closed -$294K – 241
2017
Q1 		$294K Buy
+6,795
New +$291K 0.09% 352

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Teza Capital Management's NBIX Position: Q3 2025 in Review

Teza Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 2,434 shares — an estimated $306K sold.

Teza Capital Management first reported a position in NBIX in Q1 2017 and held it in 14 quarters. The position peaked at $2.44M in Q4 2024. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Teza Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Teza Capital Management sold 2,434 Neurocrine Biosciences shares in Q3 2025, an estimated $306K.
  • Teza Capital Management first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 14 quarters.
  • Teza Capital Management's Neurocrine Biosciences position peaked at $2.44M in Q4 2024.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Teza Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.